



RESUME DR. EDWIN MOSES

Nationality

British

Year of birth

1954

Shares Avantium N.V.

None

Motivation for nomination

In line with Avantium's supervisory board profile, Mr. Moses adds the following desired specific knowledge and experience:

- *Proven know-how in scaling up innovative companies*

Mr. Moses has first-hand experience in scaling up innovative companies. He is a highly respected and well-recognized business leader in the life science industry, with a successful track record in creating company value and attracting finance, both in the private and public arena.

- *Extensive executive and non-executive experience*

He has made a substantial contribution at Board level (primarily as Chairman and/or CEO) to over 15 European life sciences companies.

- *International experience*

He is internationally experienced, having lived/worked for extended periods in Belgium, Germany, UK and Italy as well as in the USA. A native English speaker, he speaks German and has a working knowledge of Italian and French.

Corporate Governance

The proposal to appoint Mr. Moses is made taking into account the limitation to the number of functions as prescribed by applicable law, and Avantium's supervisory board regulations and supervisory board profile, including the diversity policy.

Mr. Moses qualifies as independent supervisory board member within the meaning of the Dutch Corporate Governance Code.

Education, experience and previous positions

Dr. Edwin Moses has a Ph.D. in Chemistry from the University of Sheffield (UK) and a Post-Doctoral Fellowship in Biophysical Chemistry from the University of Regensburg (Germany).

Edwin Moses is a serial entrepreneur and value creator in European life science companies. As CEO, he built two businesses (Ablynx NV and Oxford Asymmetry International), led their successful IPOs on the LSE, EuroNext and NASDAQ and raised over €500 million in equity and debt financing. Mr. Moses oversaw multiple deal making at Ablynx which generated ~€0.5 billion in cash, >€10 billion in potential milestones plus royalties. He was responsible for developing the business plans and implementing them. He has expertise in high value service provision to the pharmaceutical industry and in drug discovery and development. His primary focus is on high growth businesses and change management. Mr. Moses has 25 years of Board level experience in more than 10 companies, mostly as Chairman.

Current positions

2019 – Present, Advisor to Cube Management BVBA

2019 – Present, Member of GIMV Life Sciences Advisory Board

2018 – Present, Chairman of Achilles Therapeutics

2018 – Present, Chairman of Virion Biotherapeutics

2018 – Present, Chairman of Evox Therapeutics